Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.11% | 32.36% | 36.94% | 70.59% | 129.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.68% | 45.89% | 54.39% | 53.21% | 43.31% |
| Operating Income | -49.68% | -45.89% | -54.39% | -53.21% | -43.31% |
| Income Before Tax | -28.02% | -22.64% | -30.58% | -29.64% | -24.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.02% | -22.64% | -30.58% | -29.64% | -24.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.02% | -22.64% | -30.58% | -29.64% | -24.73% |
| EBIT | -49.68% | -45.89% | -54.39% | -53.21% | -43.31% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -10.23% | -1.35% | -3.62% | 0.78% | -2.11% |
| Normalized Basic EPS | -10.33% | -1.47% | -3.64% | 0.68% | -2.20% |
| EPS Diluted | -10.23% | -1.35% | -3.62% | 0.78% | -1.88% |
| Normalized Diluted EPS | -10.33% | -1.47% | -3.64% | 0.68% | -2.20% |
| Average Basic Shares Outstanding | 15.63% | 20.04% | 25.17% | 30.48% | 22.71% |
| Average Diluted Shares Outstanding | 15.63% | 20.04% | 25.17% | 30.48% | 22.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |